Immunomodulators Market Outlook 2031:
The global immunomodulators market size was valued at USD 217.10 Million in 2022 and is projected to reach USD 389.17 Million by 2031, expanding at a CAGR of 6.7% during the forecast period 2023 - 2031, attributed to the rising prevalence of chronic diseases such as cancer, asthma, multiple sclerosis, and allergic conditions. Moreover, the formation or introduction of genesis of new biologics response modifiers presents a key aspect for the market growth.
Immunomodulators are types of medications and agents that ensure a proper function of the immune system by balancing the immune response. Using these drugs, the resistance of the body is enhanced against various infections. These are widely used to avoid the rejection of organs during transplantation.
The launch of several novel drugs took place to fight against various diseases that include Crohn’s disease, rheumatoid disease, and others. For instance, SQX770, used for the treatment of recurrent herpes labialis, was a tropical immunomodulator that received positive results in phase 2 trials in 2019.
Later, it became the first and only drug to be approved by the US Food and Drug Administration (FDA) to be used for treatment after completing the phase 3 trials with prominent and positive results.
The COVID-19 pandemic had a significant impact on the global immunomodulators market attributed to the increase in the sales of products that are used in the emergency treatment of the COVID patients. Despite the pandemic, a balance has been made between the supply and demand chains by several pharmaceutical companies. These companies are continuously working on enhancing their research & development and improving the management of their supply chain.
Immunomodulators Market Trends, Drivers, Restraints, and Opportunities
- For the treatment of Crohn’s disease, the early immunomodulator therapy is widely adopted is a key driver helping the market growth.
- Immunotherapeutic agents are being developed and are under clinical trials due to which the immunomodulators market is expected to register considerable growth.
- Presence of several unmet clinical needs for the treatment of immune disorders including rheumatoid arthritis especially in developing countries is anticipated to fuel the market growth in the coming years.
- Strict & rigid regulations imposed for the approval of immunomodulator antibodies are estimated to act as a restraining point that can hamper the market expansion during the forecast period.
- Ongoing research & development programs in order to provide advanced patient care and increasing candidates of pipeline for the treatment of several diseases are the key opportunities for the market.
Scope of the Immunomodulators Market Report
The report on the global immunomodulators market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Immunomodulators Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Products (Immunostimulants [Antibodies, Vaccines, and Others] and Immunosuppressants [Antimetabolitics, Antibodies, Glucocoriticoids, Calcineurin Inhibitors, and Others]) and Applications (HIV, Respiratory, Oncology, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Eli Lily and Co.; F.Hoffmann-La Roche Ltd.; Biogen; Bristol-Myers & Squibb Co.; Teva Pharmaceuticals Industries Ltd.; Merck Sharp & Dohme Corp.; Amgen Inc.; and Novartis AG
|
Immunomodulators Market Segment Insights
Immunosuppressant is expected to dominate the market
On the basis of products, the global immunomodulators market is bifurcated into immunostimulants and immunosuppressants. The immunostimulants segment is further divided into antibodies, vaccines, and others while the immunosuppressant segment is divided into antimetabolitics, antibodies, glucocoriticoids, calcineurin inhibitors, and others.
The immunosuppressant segment held a major share of the market in 2019 and is expected to dominate the market in the coming years owing to the availability of a wide range of therapeutics including monoclonal antibodies, cyclosporine, azathioprine, and corticosteroids. Moreover, a wide range of immunosuppressant drugs are available for the treatment of several autoimmune diseases including alopecia areata, psoriasis, lupus, and others.
Others segment is anticipated to grow at a significant rate
Based on applications, the market is segmented into HIV, respiratory, oncology, and others. The others segment is anticipated to grow at a significant rate during the projected period owing to various initiatives taken to develop drugs that can fulfill the unmet needs of several infectious diseases.
Furthermore, the segment growth is attributed to the expected launch of immunomodulatory therapies that can be used for the treatment of multiple sclerosis.
North America is estimated to dominate the market
In terms of regions, the global immunomodulators market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a large revenue share of the market in 2019 and is estimated to dominate the market during the forecast period owing to the high number of the targeted population having diseases.
Moreover, the rising demand for advanced therapy for the treatment of multiple sclerosis using these immunotherapeutic agents and immunomodulator-based treatment by several end-users in the region present another major factor driving the regional market growth. Various governments’ supportive initiatives to ensure a high level of public awareness about the disease and availability of its therapy in the region are expected to help boost the regional market growth.
Segments
The global immunomodulators market has been segmented on the basis of
Products
- Immunostimulants
- Antibodies
- Vaccines
- Others
- Immunosuppressants
- Antimetabolitics
- Antibodies
- Glucocoriticoids
- Calcineurin Inhibitors
- Others
Applications
- HIV
- Respiratory
- Oncology
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the global immunomodulators market are Eli Lily and Co.; F.Hoffmann-La Roche Ltd.; Biogen; Bristol-Myers & Squibb Co.; Teva Pharmaceuticals Industries Ltd.; Merck Sharp & Dohme Corp.; Amgen Inc.; and Novartis AG.
Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, mergers, partnerships, and production capacity expansion to increase their market position and expand their consumer base globally. Moreover, branded therapies are anticipated to expire, which is expected to provide a profitable growth to the market.
Request For Customization
Enquiry Before Buying
Speak With Analyst
